Hereditary Hemorrhagic Telangiectasia - 26 Studies Found
Recruiting |
: Cerebral Hemorrhage Risk in Hereditary Hemorrhagic Telangiectasia : Hereditary Hemorrhagic Telangiectasia : 2010-07-07 |
Completed |
: Tranexamic Acid and Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) : Hereditary Hemorrhagic Telangiectasia : 2009-12-11 :
|
Completed |
: Submucosal Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT) : Hereditary Hemorrhagic Telangiectasia (HHT) : 2011-07-19 : Drug: Submucosal Bevacizumab 200 mg Bevacizumab, injected submucosally- 100 mg per nostril |
Completed |
: Topical Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT) : Hereditary Hemorrhagic Telangiectasia (HHT) : 2011-07-18 : Drug: Bevacizumab The bevacizumab will then be sprayed by the treating physician in the clinic, under di |
Active, not recruiting |
: Efficacy of Thalidomide in the Treatment of Hereditary Hemorrhagic Telangiectasia :
: 2011-11-28 : Drug: Thalidomide Eligible patients will receive thalidomi |
Completed |
: Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia :
: 2011-07-01 : Drug: Sodium tetradecyl sulfate (sotradecol) 3% Sodium tetradecyl sulfate (STS) is mixed with air at a r |
Withdrawn |
: Ranibizumab for the Management of Recurrent Nosebleeds in Patients With Hereditary Hemorrhagic Telangiectasia (HHT) :
: Drug: Ranibizumab Patients will be treated with a total of 4 applications of ranibizumab in a fine mist |
Withdrawn |
: Pomalidomide in Hereditary Hemorrhagic Telangiectasia and Transfusion-Dependent Vascular Ectasia: a Phase I Study :
|
Completed |
: Study of the Natural History and Genotype-Phenotype Correlations of Hereditary Hemorrhagic Telangiectasia Patients : Hereditary Hemorrhagic Telangiectasia : 2000-02-24 |
Terminated |
: Efficacy of a Bevacizumab Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) :
: 2014-04-01 :
|